Journal:

Article Title: Pharmacokinetics and pharmacodynamics of Phor21- β CG(ala), a lytic peptide conjugate

doi: 10.1211/jpp.60.11.0004

Figure Lengend Snippet: Structure of Phor21-βCG(ala).

Article Snippet: Phor21- β CG(ala) (MW 4010; Lot No. 03TR1211) was synthesized by SynPep Corporation (Dublin, CA, USA) and maintained at 5°C.

Techniques:

Journal:

Article Title: Pharmacokinetics and pharmacodynamics of Phor21- β CG(ala), a lytic peptide conjugate

doi: 10.1211/jpp.60.11.0004

Figure Lengend Snippet: Growth inhibitory activity of Phor21-βCG(ala) against human prostate PC-3 and Caco-2 adenocarcinoma cell lines following the 6-h treatment. Data are means ± s.e., n = 8 per concentration.

Article Snippet: Phor21- β CG(ala) (MW 4010; Lot No. 03TR1211) was synthesized by SynPep Corporation (Dublin, CA, USA) and maintained at 5°C.

Techniques: Activity Assay, Concentration Assay

Journal:

Article Title: Pharmacokinetics and pharmacodynamics of Phor21- β CG(ala), a lytic peptide conjugate

doi: 10.1211/jpp.60.11.0004

Figure Lengend Snippet: Inhibition of proliferation of PC-3.luc cells by Phor21-βCG. Mice (n = 8 per group) were inoculated with PC-3.luc into the thigh muscle and treated with 0.8 mg kg−1 of Phor21-βCG-ala (q.d.x3, i.v.) on days 1–3, 7–9, 14–16 or 21–23 after the inoculation. At necropsy on days 4, 10, 17 and 24 following the treatment, the numbers of PC-3.luc cells in the muscle were counted. Phor21-βCG(ala) produced a highly significant reduction in PC-3.luc cells in comparison with the controls (*P < 0.004, one-way analysis of variance).

Article Snippet: Phor21- β CG(ala) (MW 4010; Lot No. 03TR1211) was synthesized by SynPep Corporation (Dublin, CA, USA) and maintained at 5°C.

Techniques: Inhibition, Produced, Comparison

Journal:

Article Title: Pharmacokinetics and pharmacodynamics of Phor21- β CG(ala), a lytic peptide conjugate

doi: 10.1211/jpp.60.11.0004

Figure Lengend Snippet: Mass spectra of Phor21-βCG(ala) separated from mouse plasma. The spectra showed multiply charged ions of the peptide at m/z 1003.5, (M+4H)+4; 803, (M+5H)+5; and 669.3, (M+6H)+6.

Article Snippet: Phor21- β CG(ala) (MW 4010; Lot No. 03TR1211) was synthesized by SynPep Corporation (Dublin, CA, USA) and maintained at 5°C.

Techniques: Clinical Proteomics

Journal:

Article Title: Pharmacokinetics and pharmacodynamics of Phor21- β CG(ala), a lytic peptide conjugate

doi: 10.1211/jpp.60.11.0004

Figure Lengend Snippet: Stability of Phor21-βCG(ala) in mouse, rat, dog or human plasma at 37°C.

Article Snippet: Phor21- β CG(ala) (MW 4010; Lot No. 03TR1211) was synthesized by SynPep Corporation (Dublin, CA, USA) and maintained at 5°C.

Techniques: Clinical Proteomics

Journal:

Article Title: Pharmacokinetics and pharmacodynamics of Phor21- β CG(ala), a lytic peptide conjugate

doi: 10.1211/jpp.60.11.0004

Figure Lengend Snippet: Concentrations of Phor21-βCG(ala) in rodent plasma or RBCs over time following intravenous administration of 0.8 or 8 mg kg−1 to mice (A), or 6 mg kg−1 to the catheterized rats (B). Data are means ± s.e., n = 3 or 4 per time point.

Article Snippet: Phor21- β CG(ala) (MW 4010; Lot No. 03TR1211) was synthesized by SynPep Corporation (Dublin, CA, USA) and maintained at 5°C.

Techniques: Clinical Proteomics

Journal:

Article Title: Pharmacokinetics and pharmacodynamics of Phor21- β CG(ala), a lytic peptide conjugate

doi: 10.1211/jpp.60.11.0004

Figure Lengend Snippet: Pharmacokinetic parameters for mice and rats dosed intravenously with Phor21- β CG(ala)

Article Snippet: Phor21- β CG(ala) (MW 4010; Lot No. 03TR1211) was synthesized by SynPep Corporation (Dublin, CA, USA) and maintained at 5°C.

Techniques: